CD8A and neoplasm: Whole tumor antigen with its vast amount of characterized and uncharacterized T cell epitopes available for activating CD4+ T helper (Th) and CD8+ cytotoxic lymphocytes (CTLs) simultaneously, represents an attractive alternative source of antigens to tumor-derived peptides and full-length recombinant tumor proteins for dendritic cell (DC)-based immunotherapy [1].